Karyopharm Therapeutics (KPTI) Amortization of Deferred Charges (2019 - 2025)

Karyopharm Therapeutics (KPTI) has 7 years of Amortization of Deferred Charges data on file, last reported at $2.4 million in Q4 2025.

• Quarterly Amortization of Deferred Charges rose 3.73% year-over-year to $2.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10.5 million (up 65.58% YoY) and the FY2025 annual result came in at $10.5 million, up 65.58% from the prior year.
• Amortization of Deferred Charges fell to $2.4 million in Q4 2025, from $2.8 million in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $2.8 million in Q3 2025 to a low of $191000.0 in Q1 2021.
• A 5-year average of $966050.0 and a median of $206500.0 in 2023 frame the typical range for Amortization of Deferred Charges.
• Annual changes were most pronounced in 2021 — Amortization of Deferred Charges tumbled 90.64% — and 2025, when it surged 1137.02%.
• Tracing KPTI's Amortization of Deferred Charges over 5 years: stood at $199000.0 in 2021, then advanced by 5.53% to $210000.0 in 2022, then advanced by 3.33% to $217000.0 in 2023, then surged by 986.18% to $2.4 million in 2024, then gained by 3.73% to $2.4 million in 2025.
• The last three Amortization of Deferred Charges figures came in at $2.4 million (Q4 2025), $2.8 million (Q3 2025), and $2.7 million (Q2 2025), per Business Quant data.